COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population

Article Figures & Data

Table 1

-Sociodemographic characteristics and clinical parameters of patients.

SD - standard deviation, MDMA - 3,4-Methylenedioxymethamphetamine, COMT - Catechol-O-methyltransferase

Table 2

- Comparison of genotype distributions of COMT Val158Met polymorphism in patients with the control.

Genotype	MDMA	Control	OR	95% CI	P-value
COMTVal158Met	n=^a (%)	n=95 (%)
Met/Met	12 (14.6)	30 (31.6)	2.692^*	1.272-5.698^*	0.008^*
Val/Met	34 (41.5)	32 (33.7)	0.717^*	0.389-1.322^*	0.286^*
Val/Val	36 (43.9)	33 (34.7)	0.680^*	0.371-1.248^*	0.212^*
Allele
Met	58 (35.4)	92 (48.4)
Val	106 (64.6)	98 (51.6)	1.716*	1.118-2.633*	0.013*

MDMA, 3,4-Methylenedioxymethamphetamine; an= 82; OR, odds ratio; CI, confidence interval; *Pearson chi-square

Table 3

- Comparison of genotype distributions of COMT Val158Met in patients due to psychotic symptoms.

Psychotic Symptoms/Genotype	Yes	No	OR	95% CI	P-value
COMTVal158Met	n= a (%)	n=37 (%)
Met/Met	5 (11.1)	7 (18.9)	0.536*	0.155-1.854*	0.320*
Val/Met	25 (55.6)	9 (24.3)	3.889*	1.498-10.094*	0.004*
Val/Val	15 (33.3)	21 (56.8)	2.625*	1.069-6.446*	0.033*
Allele
Met	35 (38.9)	23 (31.1)
Val	55 (61.1)	51 (68.9)	1.411*	0.737-2.702*	0.298*